BioSpace News Archive

Accumulated problems, contradictions. Dead end, we need to go back. You cannot continue further. Complete impossibility to continue. Rejection of an idea. Hard sanctions. Fatal error.

Pipeline

Moderna Cans 3 mRNA Vaccines, Secures $1.5B Loan in Quest for 10% Growth

Amid an aggressive savings push, Moderna has cut three assets and taken on a loan to increase “flexibility.”

November 21, 2025

·

2 min read

·

Tristan Manalac

Isometric businessman tightrope walker is on the rope. Teetering on the cable. Business challenge and risk concept. Simple minimal design. Trendy style graphic. Flat vector illustration.

Multiple sclerosis

J&J, Contineum Fail ‘Risky’ Mid-Stage Multiple Sclerosis Trial

While expressing disappointment, William Blair analysts were unsurprised by the Phase II failure, having assigned the VISTA study a high level of risk given the “mixed” performance of a similar drug in a prior multiple sclerosis study.

November 21, 2025

·

2 min read

·

Tristan Manalac

Poznan, Poland - 5 October 2024: GSK -Glaxosmithkline headquarters office building in Poznan.

Legal

UPDATE: GSK’s Tesaro Sues AnaptysBio Over Current Jemperli Contract; Anaptys Countersues

After GSK subsidiary Tesaro filed a lawsuit Thursday claiming that AnaptysBio breached “certain requirements” under their 2014 license agreement involving GSK’s Jemperli, Anaptys responded Friday morning.

November 21, 2025

·

3 min read

·

Tristan Manalac

Vector Illustration Of Athletes Running On Race Track

Regulatory

6 Biotechs With a Shot at the FDA’s Platform Technology Designation

After revoking Sarepta’s award in July and awarding one to Krystal last month, the FDA’s platform technology designation program appears to be back on track. These six biotechs could be on the regulator’s radar.

November 21, 2025

·

9 min read

·

Tristan Manalac

Rare diseases

FDA Probing Patient Death Linked to Takeda’s Enzyme Replacement Therapy

The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the protein the therapy replaces.

November 21, 2025

·

1 min read

·

Dan Samorodnitsky

Press Releases

RadNet’s DeepHealth Announces Wichita Radiological Group as First Operations Suite™ Customer

November 21, 2025

·

10 min read

Press Releases

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression